JP7729561B2 - 多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞 - Google Patents

多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞

Info

Publication number
JP7729561B2
JP7729561B2 JP2022506455A JP2022506455A JP7729561B2 JP 7729561 B2 JP7729561 B2 JP 7729561B2 JP 2022506455 A JP2022506455 A JP 2022506455A JP 2022506455 A JP2022506455 A JP 2022506455A JP 7729561 B2 JP7729561 B2 JP 7729561B2
Authority
JP
Japan
Prior art keywords
cells
domain
seq
car
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542443A5 (https=
JP2022542443A (ja
Inventor
アントニオ ベアトリス マルティン
イスピッツア アルバロ ウルバノ
アミル ロレーナ ペレス
ロドリゲス ギリェルモ スニェ
オテロ マネル フアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Clinic per a la Recerca Biomedica FCRB
Original Assignee
Fundacio Clinic per a la Recerca Biomedica FCRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Clinic per a la Recerca Biomedica FCRB filed Critical Fundacio Clinic per a la Recerca Biomedica FCRB
Publication of JP2022542443A publication Critical patent/JP2022542443A/ja
Publication of JP2022542443A5 publication Critical patent/JP2022542443A5/ja
Application granted granted Critical
Publication of JP7729561B2 publication Critical patent/JP7729561B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
JP2022506455A 2019-08-02 2020-08-03 多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞 Active JP7729561B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382673.2 2019-08-02
EP19382673 2019-08-02
PCT/EP2020/071831 WO2021023721A1 (en) 2019-08-02 2020-08-03 Car t-cells against bcma for the treatment of multiple myeloma

Publications (3)

Publication Number Publication Date
JP2022542443A JP2022542443A (ja) 2022-10-03
JP2022542443A5 JP2022542443A5 (https=) 2023-08-14
JP7729561B2 true JP7729561B2 (ja) 2025-08-26

Family

ID=67658496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506455A Active JP7729561B2 (ja) 2019-08-02 2020-08-03 多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞

Country Status (18)

Country Link
US (1) US12509525B2 (https=)
EP (2) EP4272837A3 (https=)
JP (1) JP7729561B2 (https=)
AU (1) AU2020325690A1 (https=)
CA (1) CA3148930A1 (https=)
DK (1) DK4007777T5 (https=)
ES (1) ES2971033T3 (https=)
FI (1) FI4007777T3 (https=)
HR (1) HRP20240037T1 (https=)
HU (1) HUE064890T2 (https=)
LT (1) LT4007777T (https=)
PL (1) PL4007777T3 (https=)
PT (1) PT4007777T (https=)
RS (1) RS65094B1 (https=)
SI (1) SI4007777T1 (https=)
SM (1) SMT202400013T1 (https=)
WO (1) WO2021023721A1 (https=)
ZA (1) ZA202201166B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021397A (ko) * 2022-02-09 2025-02-12 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 면역 관련 질환을 표적으로 하는 항-bcma car, 조성물 및 이의 방법
EP4378953A1 (en) * 2022-12-02 2024-06-05 Universitat de Barcelona Cd229 targeting moiety for the tratment of cd229 positive cancer
WO2025141187A1 (en) * 2023-12-29 2025-07-03 Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre T cells expressing anti-bcma/anti-cd3 bispecific antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535002A (ja) 2012-11-01 2015-12-07 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
JP2017515470A (ja) 2014-04-30 2017-06-15 マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ−ゲマインシャフト Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体
WO2017211900A1 (en) 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Chimeric antigen receptor and car-t cells that bind bcma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
NO3051026T3 (https=) 2011-10-21 2018-07-28
ES2546743B1 (es) 2014-03-28 2016-07-07 Institut D'investigació Biomèdica De Bellvitge (Idibell) Marcadores mitocondriales de enfermedades neurodegenerativas
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
CN108004259B (zh) * 2016-11-02 2020-06-30 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108285489A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN108395478A (zh) 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
MX2019013514A (es) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
ES2953362T3 (es) 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535002A (ja) 2012-11-01 2015-12-07 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
JP2017515470A (ja) 2014-04-30 2017-06-15 マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ−ゲマインシャフト Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体
WO2017211900A1 (en) 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Chimeric antigen receptor and car-t cells that bind bcma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Julia BLUHM et al.，Molecular Therapy，2018年，Vol. 26, No. 8，pp. 1906-1920

Also Published As

Publication number Publication date
US20220267459A1 (en) 2022-08-25
AU2020325690A1 (en) 2022-03-03
ZA202201166B (en) 2022-10-26
DK4007777T5 (da) 2024-08-05
DK4007777T3 (da) 2024-01-15
PL4007777T3 (pl) 2024-03-11
SI4007777T1 (sl) 2024-03-29
EP4272837A3 (en) 2024-02-28
FI4007777T3 (fi) 2024-01-11
CA3148930A1 (en) 2021-02-11
US12509525B2 (en) 2025-12-30
SMT202400013T1 (it) 2024-03-13
EP4272837A2 (en) 2023-11-08
EP4007777A1 (en) 2022-06-08
WO2021023721A1 (en) 2021-02-11
HUE064890T2 (hu) 2024-04-28
HRP20240037T1 (hr) 2024-03-29
RS65094B1 (sr) 2024-02-29
JP2022542443A (ja) 2022-10-03
PT4007777T (pt) 2024-01-12
ES2971033T3 (es) 2024-06-03
LT4007777T (lt) 2024-02-12
EP4007777B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
CN113286879B (zh) 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子
JP7590737B2 (ja) ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞
KR20240156612A (ko) 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용
JP7729561B2 (ja) 多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞
JP7545139B2 (ja) Ｂ細胞急性リンパ芽球性白血病（ｂ－ａｌｌ）の処置のためのｃｄ２２標的化部分
CN117858719A (zh) 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
KR20250017174A (ko) 면역세포의 조절 시스템
EP4378953A1 (en) Cd229 targeting moiety for the tratment of cd229 positive cancer
EP4417623A1 (en) Ccr9 targeting moiety for the treatment of ccr9-positive cancer
HK40116152A (zh) 用於治疗cd1a阳性癌症的car t细胞
CN119790063A (zh) 免疫细胞疗法
HK40120698A (zh) 用於治疗cd1a阳性癌症的人源化cd1a靶向部分
KR20220095228A (ko) 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220328

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250805

R150 Certificate of patent or registration of utility model

Ref document number: 7729561

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150